Proclara Biosciences Financing
Proclara Biosciences, Inc., Corporation just released form D announcing $47.00 million equity financing. This is a new filing. Proclara Biosciences was able to sell $43.04 million. That is 91.56% of the financing round. The total financing amount was $47.00 million. The offering form was filed on 2016-11-30. The reason for the financing was: unspecified. The fundraising still has about $3.96 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Proclara Biosciences is based in Massachusetts. The firm’s business is Biotechnology. The form D was signed by Hampus Hillerstrom Executive Vice President and Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 222 Third Street, Cambridge, Ma, Massachusetts, 02142. Franz Hefti, Ph.D. is the related person in the form and it has address: 222 Third Street, Cambrdige, Ma, Massachusetts, 02142. Link to Proclara Biosciences Filing: 000114036116088139.
Analysis of Proclara Biosciences Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering amount. Proclara Biosciences sold 91.56% of the offering. The financing is still open. Could this mean that the trust in Proclara Biosciences is high? The average fundraising size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 1,297.26% bigger than the average for companies in the Biotechnology sector. The minimum investment for this offering is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Proclara Biosciences Also
The Form D signed by Hampus Hillerstrom might help Proclara Biosciences, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.